Section Arrow
XLO.NASDAQ
- Xilio Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2025/07/16 16:24 EDT
After Hours
Last
 0.7227
-0.0077 (-1.05%)
Bid
0.7204
Ask
0.7375
High 0.7375 
Low 0.7227 
Volume 410 
Regular Hours
Last
 0.7304
+0.0173 (+2.43%)
Day High 
0.7371 
Prev. Close
0.7131 
1-M High
0.745 
Volume 
208.21K 
Bid
0.7204
Ask
0.7375
Day Low
0.7101 
Open
0.7265 
1-M Low
0.65 
Market Cap 
36.93M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.72 
20-SMA 0.7 
50-SMA 0.75 
52-W High 1.7 
52-W Low 0.62 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.65/-4.23
Enterprise Value
43.88M
Balance Sheet
Book Value Per Share
0.21
Cash Flow
Cash Flow Yield
0.45
Income Statement
Total Revenue
6.34M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
APMAptorum Group Limited1.94+0.9702+100.04%2.77PE
After Hours 2 +0.06 +3.09%
TNFATNF Pharmaceuticals Inc.0.109+0.0028+2.64%-- 
After Hours 0.1008 -0.0082 -7.52%
NCNANuCana plc0.0502--0.000%-- 
After Hours 0.0503 +0.0001 +0.20%
BRNSBarinthus Biotherapeutics plc1.42+0.4+39.22%-- 
After Hours 1.34 -0.08 -5.63%
WINTWindtree Therapeutics Inc.0.9+0.0714+8.62%0.84PE
After Hours 0.8596 -0.0404 -4.49%
Quotes are at least 15-min delayed:2025/07/16 16:24 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.